

原著			朝日生命成人病研究所
論文名	報告者	発表誌名	リンク
1 Impact of patient attitudes and beliefs to insulin therapy upon initiation, and their attitudinal changes after initiation: the DAWN Japan study.	M. Odawara, H. Ishii, N. Tajima, Y. Iwamoto	Curr Med Res Opin. 32:681–686, 2016	<a href="https://doi.org/10.1185/03007995.2015.1136605">doi: 10.1185/03007995.2015.1136605</a>
2 Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.	H. Sakura, N. Hashimoto, K. Sasamoto, H. Ohashi, S. Hasumi, N. Ujihara, T. Kasahara, O. Tomonaga, H. Nunome, M. Honda, Y. Iwamoto; JAMP Study Investigators.	BMC Endocr Disord. 2016 Dec 1;16:70.	<a href="https://doi.org/10.1186/s12902-016-0149-z">doi: 10.1186/s12902-016-0149-z</a>
3 Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes.	T. Takao, M. Suka, H. Yanagisawa, Y. Iwamoto	J Diabetes Investig. 2016 Dec 6.	<a href="https://doi.org/10.1111/jdi.12610">doi: 10.1111/jdi.12610</a>
4 Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.	Y. Onishi, K. Yamada, J. Zacho, J. Ekelund, Y. Iwamoto	J Diabetes Investig. 2016 Aug 25.	<a href="https://doi.org/10.1111/jdi.12569">doi: 10.1111/jdi.12569</a>
5 Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.	A. Kushiya, T. Kikuchi, K. Tanaka, T. Tahara, T. Takao, Y. Onishi, Y. Yoshida, S. Kawazu, Y. Iwamoto	World J Diabetes. 7:230–238, 2016	<a href="https://doi.org/10.4239/wjd.v7.i11.230">doi: 10.4239/wjd.v7.i11.230</a>
6 C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus.	R. Sonoda, K. Tanaka, T. Kikuchi, Y. Onishi, T. Takao, T. Tahara, Y. Yoshida, N. Suzawa, S. Kawazu, Y. Iwamoto, A. Kushiya	PLoS One. 2016 Feb 5;11:e0147303.	<a href="https://doi.org/10.1371/journal.pone.0147303">doi: 10.1371/journal.pone.0147303</a>
7 Body mass index and the risk of cancer incidence in patients with type 2 diabetes in Japan: Results from the National Center Diabetes Database.	(共同研究) R. Yamamoto-Honda, Y. Takahashi, Y. Yoshida, S. Kwazu, Y. Iwamoto, H. Kajio, H. Yanai, S. Mishima, T. Shimbo, M. Noda	J Diabetes Investig 7:908–914, 2016	<a href="https://doi.org/10.1111/jdi.12522">doi: 10.1111/jdi.12522</a>
8 Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study.	(共同研究) A. Kato, Y. Fujimaki, S. Fujimori, A. Isogawa, Y. Onishi, R. Suzuki, T. Yamauchi, K. Ueki, T. Kadowaki, H. Hashimoto	BMJ Open Diabetes Res Care. 4:e000156, 2016	<a href="https://doi.org/10.1136/bmjdr-2015-000156">doi: 10.1136/bmjdr-2015-000156</a>
9 Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.	(共同研究) H. Seino, Y. Onishi, Y. Naito, M. Komatsu	Diabetol Metab Syndr. 2016 Jun 1;8:36.	<a href="https://doi.org/10.1186/s13098-016-0151-7">doi: 10.1186/s13098-016-0151-7</a>
10 Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.	(共同研究) E. Araki, Y. Onishi, M. Asano, H. Kim, E. Ekholm, E. Johnsson, T. Yajima	J Diabetes Investig. 7:555–564, 2016	<a href="https://doi.org/10.1111/jdi.12453">doi: 10.1111/jdi.12453</a>
11 Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: DAISY trial.	(共同研究) E. Araki, Y. Onishi, M. Asano, H. Kim, T. Yajima	Diabetes Obes Metab. 2016 Dec 17.	<a href="https://doi.org/10.1111/dom.12853">doi: 10.1111/dom.12853</a>

原著			朝日生命成人病研究所
論文名	報告者	発表誌名	リンク
12 Involvement of resistin-like molecule $\beta$ in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice	(共同研究) H. Okubo, A. Kushiyama, H. Sakoda, Y. Nakatsu, M. Iizuka, N. Taki, M. Fujishiro, T. Fukushima, H. Kamata, A. Nagamachi, T. Inaba, F. Nishimura, H. Katagiri, T. Asahara, Y. Yoshida, O. Chonan, J. Encinas, T. Asano	Sci Rep. 2016 Jan 28;6:20157.	<a href="https://doi.org/10.1038/srep20157">doi:10.1038/srep20157</a>
13 Physiological and Pathogenic Roles of Prolyl Isomerase Pin1 in Metabolic Regulations via Multiple Signal Transduction Pathway Modulations.	(共同研究) Y. Nakatsu, Y. Matsunaga, T. Yamamotoya, K. Ueda, Y. Inoue, K. Mori, H. Sakoda, M. Fujishiro, H. Ono, A. Kushiyama, T. Asano	Int J Mol Sci. 2016 Sep 7;17. pii: E1495.	<a href="https://doi.org/10.3390/ijms17091495">doi:10.3390/ijms17091495</a> .
14 Epicatechin downregulates adipose tissue CCL19 expression and thereby ameliorates diet-induced obesity and insulin resistance.	(共同研究) T. Sano, S. Nagayasu, S. Suzuki, M. Iwashita, A. Yamashita, T. Shinjo, T. Sanui, A. Kushiyama, T. Kanematsu, T. Asano, F. Nishimura	Nutr Metab Cardiovasc Dis. 2016 Nov 23	<a href="https://doi.org/10.1016/j.numecd.2016.11.008">doi:10.1016/j.numecd.2016.11.008</a>
15 Marked elevation of plasma levels of oxidative stress-responsive apoptosis inducing protein in dialysis patients	K. Tanaka, T. Yao, T. Fujimura, K. Murayama, S. Fukuda, K. Okumura, Y. Seko	Kidney Int Rep. 1:321–324, 2016	<a href="https://doi.org/10.1016/j.ekir.2016.08.011">doi:10.1016/j.ekir.2016.08.011</a> .
16 Plasma Levels of Oxidative stress-Responsive Apoptosis Inducing Protein (ORAIP) in Rats Subjected to Physicochemical Oxidative Stresses.	T. Yao, T. Fujimura, K. Murayama, Y. Seko	Bioscience Rep. 2016;36:e00317.	<a href="https://doi.org/10.1042/BSR20160044">doi:10.1042/BSR20160044</a> .
17 Plasma levels of oxidative stress-responsive apoptosis inducing protein (ORAIP) in patients with atrial fibrillation.	T. Yao, K. Tanaka, T. Fujimura, K. Murayama, S. Fukuda, K. Okumura, Y. Seko	Int J Cardiol. 222:528–530, 2016	<a href="https://doi.org/10.1016/j.ijcard.2016.08.005">doi:10.1016/j.ijcard.2016.08.005</a> .
18 Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.	(共同研究) Y. Hirata, T. Serizawa, S. Shichijo, N. Suzuki, K. Sakitani, Y. Hayakawa, A. Yamada, K. Koike	Int J Infect Dis. 51:66–69, 2016	<a href="https://doi.org/10.1016/j.ijid.2016.08.019">doi:10.1016/j.ijid.2016.08.019</a>
19 Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.	(共同研究) S. Shichijo, Y. Hirata, R. Niikura, Y. Hayakawa, A. Yamada, S. Mochizuki, K. Matsuo, Y. Isomura, M. Seto, N. Suzuki, H. Suzuki, S. Yamamoto, T. Sugimoto, T. Omae, M. Okamoto, H. Watabe, G. Togo, N. Takano, K. Fukui, Y. Ito, K. Koike	J Dig Dis. 17:670–675, 2016	<a href="https://doi.org/10.1111/1751-2980.12398">doi: 10.1111/1751-2980.12398</a> .
20 TGF- $\beta$ Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota.	(共同研究) S. Ihara, Y. Hirata, T. Serizawa, N. Suzuki, K. Sakitani, H. Kinoshita, Y. Hayakawa, H. Nakagawa, H. Ijichi, K. Tateishi, K. Koike	J Immunol. 196:4603–4613, 2016	<a href="https://doi.org/10.4049/jimmunol.1502548">doi:10.4049/jimmunol.1502548</a> .

原著			朝日生命成人病研究所	
論文名	報告者	発表誌名	リンク	
21	Family history is an independent risk factor for the progression of gastric atrophy among patients with Helicobacter pylori infection.	(共同研究) T. Nishizawa, H. Suzuki, K. Sakitani, H. Yamashita, S. Yoshida, K. Hata, T. Kanazawa, N. Fujiwara, T. Kanai, N. Yahagi, O. Toyoshima	United European Gastroenterol J. 5:32–36, 2017 Epub 2016 Jun 22.	doi: <a href="https://doi.org/10.1177/2050640616642341">10.1177/2050640616642341</a>
22	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion.	(共同研究) T. Ikenoue, Y. Terakado, H. Nakagawa, Y. Hikiba, T. Fujii, D. Matsubara, R. Noguchi, C. Zhu, K. Yamamoto, Y. Kudo, Y. Asaoka, K. Yamaguchi, H. Ijichi, K. Tateishi, N. Fukushima, S. Maeda, K. Koike, Y. Furukawa.	Sci Rep. 2016 Apr 1;6:23899.	doi: <a href="https://doi.org/10.1038/srep23899">10.1038/srep23899</a> .